

DAFTAR PUSTAKA

1. Gesthalter YB, Billatos E, Kathuria H. Lung Cancer. Genomic and Precision Medicine: Primary Care (3rd ed). Elsevier Inc., 2017; p. 165-80
2. Morrissey K, Yuraszeck T, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin Transl Sci. 2016;9(2):89-104
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
4. Duma, N., Santana-Davila, R., & Molina, J. R. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings, 94(8), 1623–1640. 2019. doi:10.1016/j.mayocp.2019.01.01
5. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016 Jun;5(3):288-300. doi: 10.21037/tlcr.2016.06.07. PMID: 27413711; PMCID: PMC4931124.
6. David Myers AJ, Wallen Affiliations JM. Lung Adenocarcinoma Continuing Education Activity [Internet]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK519578/?report=printable>
7. Dolan RD, McSorley ST, Horgan PG, Laird B, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis. Crit Rev Oncol Hematol (2017) 116:134–46. doi: 10.1016/j.critrevonc.2017.06.002
8. Takenaka Y, Oya R, Kitamiura T, Ashida N, Shimizu K, Takemura K, et al.. Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta-analysis. Head Neck (2018) 40:2714–23. doi: 10.1002/hed.25366
9. Oh D, Pyo J-S, Son BK. Prognostic roles of inflammatory markers in pancreatic cancer: Comparison between the neutrophil-to-Lymphocyte ratio and platelet-to-Lymphocyte ratio. Gastroenterol Res Pract (2018) 9745601. doi: 10.1155/2018/9745601



10. Lim JU, Yeo CD, Kang HS, Park CK, Kim JS, Kim JW, et al. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. *PLoS One*. 2018;13(7):1–13.
11. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. *Nat Rev Dis Prim*. 2015;1:1–16.
12. Vivero M, French CA. 2 — Respiratory Tract and Mediastinum. *Cytology: Diagnostic Principles and Clinical Correlates*. 2021.
13. Vansteenkiste J, de Ruyscher D, Eberhardt WEE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2013;24(SUPPL.6).
14. Giaccone G. DRUG EVALUATION Targeting HER1/EGFR in cancer therapy: experience with erlotinib. *Future Oncol* [Internet]. 2005;1(4):449–60. Available from: www.futuremedicine.com
15. Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, et al. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. *Journal of Clinical Oncology*. 2009 Jan 10;27(2):264–70.
16. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. P40 (Δ Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. *Modern Pathology*. 2012 Mar;25(3):405–15.
17. Zhang, Y.-C., Zhou, Q., & Wu, Y.-L. Emerging challenges of advanced squamous cell lung cancer. 2016. *ESMO Open*, 2(Suppl 1), e000129. doi:10.1136/esmoopen-2016-000129
18. Veluswamy R, Mack PC, Houldsworth J, Elkhoully E, Hirsch FR. KRAS G12C–Mutant Non–Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing. Vol. 23, *Journal of Molecular Diagnostics*. Elsevier B.V.; 2021. p. 507–20.
19. Li H, Li J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, et al. Genome transcriptome sequencing of lung cancers reveal diverse mutational and signaling events. *Genome Research*. 2012 Dec;22(12):2315–27.
20. Hirsch FR, Vigneri A, Sequist, L. V., & Engelman, J. A. Genetic Changes in SquamousCell Lung Cancer: A Review. *Journal of Thoracic Oncology*, 7(5), 924–



933. doi:10.1097/jto.0b013e31824cc33 Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao JJ, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. *Cancer Discovery*. 2017;7(6):596–609.
21. Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. *Laboratory Investigation*. 2014 Feb;94(2):129–37.
22. Ettinger DS, Wood DE, Chair V, Aisner DL, Akerley W, Bauman JR, et al. Continue NCCN Guidelines Panel Disclosures NCCN Guidelines Version 3.2020 Non-Small Cell Lung Cancer. 2020.
23. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, et al. The IASLC lung cancer staging project: Proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. *Journal of Thoracic Oncology*. 2007 Jul;2(7):593–602.
24. National Cancer Institute (2020, May 21). Small Cell Lung Cancer Treatment (PDQ®)– Patient Version. <https://www.cancer.gov/types/lung/patient/small-cell-lung-treatment-pdq>
25. American Cancer Society (2019, Oct. 1). Non-Small Cell Lung Cancer Stages. <https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/staging-nsclc.html>
26. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. *The Lancet Oncology*. 2014;15(11):e493–503. Epub 2014/10/05. pmid:25281468.
27. Mandaliya H, Jones M, Oldmeadow C, Nordman, II. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). *Translational lung cancer research*. 2019;8(6):886–94. Epub 2020/02/06. pmid:32010567.
28. Lefrançois E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic enitors. *Nature*. 2017;544(7648):105–9. Epub 2017/03/23. :28329764.
- elaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. *Current opinion in pulmonary medicine*. 2007;13(5):362–7. Epub /10/18.



pmid:17940477.

30. Rodriguez-Martinez A, Simon-Saez I, Perales S, Garrido-Navas C, Russo A, de Miguel-Perez D, et al. Exchange of cellular components between platelets
31. Rodriguez-Martinez A, Simon-Saez I, Perales S, Garrido-Navas C, Russo A, de Miguel-Perez D, et al. Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior. *Theranostics*. 2022;12(5):2150–61. pmid:35265204
32. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. *Proc Natl Acad Sci U S A* 1968;61:46-52.
33. Karachaliou Niki, et al. Platelets and their role in cancer evolution and immune system. 2015. Vol 4, No 6
34. Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-small-cell lung cancer: Role of the immune system and potential for immunotherapy. *J Thorac Oncol* [Internet]. 2015;10(7):974–84. Available from: <http://dx.doi.org/10.1097/JTO.0000000000000551>
35. Orakpoghenor O, Avazi DO, Markus T, Olaolu O. Lymphocytes : A Brief Review -. 2019;(June).
36. Qiang G, Liang C, Xiao F, Yu Q, Wen H, Song Z, et al. Prognostic significance of platelet-to-lymphocyte ratio in non-small-cell lung cancer: a meta-analysis. *OncoTargets and therapy*. 2016;9:869–76. Epub 2016/03/10. pmid:26955285.
37. Jiang L, Luan Y, Miao X, Sun C, Li K, Huang Z, et al.. Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling. *Br J Cancer* (2017) 117:695–703. doi: 10.1038/bjc.2017.214
38. Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, et al.. Platelet “first responders” in wound response, cancer, and metastasis. *Cancer Metastasis Rev* (2017) 36:199–213. doi: 10.1007/s10555-017-9682-0
39. Li Z, Riesenbergh B, Metelli A, Li A, Wu BX. “The role of platelets in tumor growth, metastasis, and immune evasion.,”. In: *Platelets*. Elsevier; (2019). p. 61. doi: 10.1016/B978-0-12-813456-6.00030-8
- erleitner C, Strähle J, Malenke E, Hinterleitner M, Henning M, Seehawer : al.. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and icts immunotherapy response in non-small cell lung cancer. *Nat*



Commun (2021) 12:7005. doi: 10.1038/s41467-021-27303-7

41. Smida T, Bruno TC, Stabile LP. Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications. *Front Oncol*. 2020 Feb 18;10:137.
42. Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, Pagan E, et al. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. *JNCI: Journal of the National Cancer Institute*. 2019 Aug 1;111(8):772–81.
43. Wang S, Cowley LA, Liu XS. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. *Molecules*. 2019 Sep 4;24(18):3214.
44. Pinto JA, Vallejos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS, et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? *ESMO Open*. 2018;3(3):e000344
45. Yu XQ, Yap ML, Cheng ES, Ngo PJ, Vaneckova P, Karikios D, et al. Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort. *Journal of Thoracic Oncology*. 2022 May;17(5):688–99.
46. Stapelfeld C, Dammann C, Maser E. Sex-specificity in lung cancer risk. *Intl Journal of Cancer*. 2020 May;146(9):2376–82.
47. Elkrief A, Richard C, Malo J, Cvetkovic L, Florescu M, Blais N, et al. Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France. *Journal of Geriatric Oncology*. 2020 Jun;11(5):802–6.
48. Luo YH, Luo L, Wampfler JA, Wang Y, Liu D, Chen YM, et al. 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study. *The Lancet Oncology*. 2019 Aug;20(8):1098–108.



antis CE, Miller KD, Dale W, Mohile SG, Cohen HJ, Leach CR, et al. Cancer statistics for adults aged 85 years and older, 2019. *CA A Cancer J Clinicians*. 2019 Nov;69(6):452–67.

nnet P, Sawyers A, Qian Y, Kozloff S, Gulati N, Donnelly D, et al.

Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. *J Immunother Cancer*. 2020 Nov;8(2):e001674.

51. Jiang M, Fares AF, Shepshelovich D, Yang P, Christiani D, Zhang J, et al. The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. *Lung Cancer*. 2021 Feb;152:58–65.
52. Chen H, Wang D, Zhong Q, Tao Y, Zhou Y, Shi Y. Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. *Cancer Immunology, Immunotherapy*. 2020;69:2413–24.
53. Oruc Z, Akbay A, Ali Kaplan M, Oruç İ, Urakçı Z, Küçüköner M, et al. A Low Body Fat Mass Ratio Predicts Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer. *Nutrition and Cancer*. 2022 Oct 21;74(9):3284–91.
54. Suster DI, Mino-Kenudson M. Molecular pathology of primary non-small cell lung cancer. *Archives of medical research*. 2020;51(8):784–98.
55. Qu Y, Emoto K, Eguchi T, Aly RG, Zheng H, Chaft JE, et al. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. *Journal of Thoracic Oncology*. 2019 Mar;14(3):482–93.
56. Hao B, Li F, Wan X, Pan S, Li D, Song C, et al. Squamous cell carcinoma predicts worse prognosis than adenocarcinoma in stage IA lung cancer patients: A population-based propensity score matching analysis. *Front Surg*. 2022 Aug 23;9:944032.
57. Bade BC, Cruz CSD. Lung cancer 2020: epidemiology, etiology, and prevention. *Clinics in chest medicine*. 2020;41(1):1–24.
58. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. *N J Med*. 2020 Aug 13;383(7):640–9.
59. Wang J, Zhang Y, Sun X, Gusdon AM, Song N, Chen L, et al. The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study. *J Cancer Res Clin Oncol*. 2018



Sep;144(9):1835–42.

60. Cuomo A, Pirozzi F, Attanasio U, Franco R, Elia F, De Rosa E, et al. Cancer risk in the heart failure population: epidemiology, mechanisms, and clinical implications. *Current Oncology Reports*. 2021;23:1–11.
61. Xiong Y, Yu Y, Yang Y, Wang L, Shi P, Deng Y, et al. Impacts of age, diabetes, gender, and access type on costs associated with vascular access among Chinese patients on hemodialysis. *The International Journal of Artificial Organs* 2021;44(5):302–9
62. Choi S, Park J. Surgical outcomes and prognosis of non-small-cell lung cancer in patients with chronic lung diseases: a retrospective analysis. *European Journal of Cardio-Thoracic Surgery*. 2020 Aug 1;58(2):357–64.
63. Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-Based lung cancer screening: A systematic review. *Lung Cancer*. 2020 Sep;147:154–86.
64. Romaszko-Wojtowicz A, Lorenc A, Buciński A, Doboszyńska A. Effects of Tobacco Smoking on the Survivability of Patients with Multiple Cancers and Single Lung Cancer. *IJERPH*. 2022 Jul 27;19(15):9179.
65. Petrillo LA, El-Jawahri A, Nipp RD, Lichtenstein MRL, Durbin SM, Reynolds KL, et al. Performance status and end-of-life care among adults with non– small cell lung cancer receiving immune checkpoint inhibitors. *Cancer*. 2020 May 15;126(10):2288–95.
66. Simcock R, Wright J. Beyond Performance Status. *Clinical Oncology*. 2020 Sep;32(9):553–61.
67. Jurisic V, Vukovic V, Obradovic J, Gulyaeva LF, Kushlinskii NE, Djordjević N. *EGFR* Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis. *Journal of Oncology*. 2020 Mar 18;2020:1–14.
68. Zhou K, Cao J, Lin H, Liang L, Shen Z, Wang L, et al. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis. *Front Oncol*. 2022 Aug 22;12:962173.



nann M, Taugner J, Roengvoraphoj O, Eze C, Käsmann L, Belka C, et al. Impact of thrombocytosis and neutrophil-to-lymphocyte ratio before start chemoradiotherapy on patient survival in inoperable stage III NSCLC. *Journal of Oncology*. 2019 Apr;30:ii36.

70. Kauffmann-Guerrero D, Kahnert K, Kiefl R, Sellmer L, Walter J, Behr J, et al. Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study. *Sci Rep.* 2021 May 25;11(1):10919.
71. Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, et al. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective multicenter study. *Advances in therapy.* 2020;37:1145–55.
72. Shen XB, Wang Y, Shan BJ, Lin L, Hao L, Liu Y, et al. Prognostic significance of platelet-to-lymphocyte ratio (PLR) and mean platelet volume (MPV) during etoposide-based first-line treatment in small cell lung cancer patients. *Cancer management and research.* 2019;8965–75.
73. Xu H, He A, Liu A, Tong W, Cao D. Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. *International Immunopharmacology.* 2019 Dec;77:105957.





REKOMENDASI PERSETUJUAN ETIK

Nomor : 638/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 6 September 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23080547	No Sponsor	
Peneliti Utama	dr. Nurul Fuadi Rahman	Sponsor	
Judul Peneliti	Hubungan Rasio Trombosit Terhadap Limfosit Dengan Prognosis Pasien Kanker Paru Bukan Sel Kecil Stadium Lanjut di RSUP Wahidin Sudirohusodo Makassar		
No Versi Protokol	1	Tanggal Versi	3 Agustus 2023
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 6 September 2023 sampai 6 September 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah



or an akhir setelah Penelitian berakhir
impangan dari prokol yang disetujui (protocol deviation / violation)
peraturan yang ditentukan